Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Fernando Macário.
Clinical Journal of The American Society of Nephrology | 2008
Piergiorgio Messa; Fernando Macário; Magdi Yaqoob; Koen Bouman; Johann Braun; Beat von Albertini; Hans Brink; Francisco Maduell; Helmut Graf; João M. Frazão; Willem Jan W. Bos; Vicente Torregrosa; Heikki Saha; Helmut Reichel; Martin Wilkie; Valter J. Zani; Bart Molemans; Dave Carter; Francesco Locatelli
BACKGROUND AND OBJECTIVESnCinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower parathyroid hormone (PTH), calcium, and phosphorus levels in dialysis patients with secondary hyperparathyroidism (SHPT). This study compared the efficacy of a cinacalcet-based regimen with unrestricted conventional care (vitamin D and phosphate binders) for achieving the stringent National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) targets for dialysis patients.nnnSTUDY DESIGNnIn this multicenter, open-label study, hemodialysis patients with poorly controlled SHPT were randomized to receive conventional care (n = 184) or a cinacalcet-based regimen (n = 368). Doses of cinacalcet, vitamin D sterols, and phosphate binders were adjusted during a 16-wk dose-optimization phase with the use of algorithms that allowed cinacalcet to be used with adjusted doses of vitamin D. The primary end point was the proportion of patients with mean intact PTH < or =300 pg/ml during a 7-wk efficacy assessment phase.nnnRESULTSnA higher proportion of patients receiving the cinacalcet-based regimen versus conventional care achieved the targets for PTH (71% versus 22%, respectively; P < 0.001), Ca x P (77% versus 58%, respectively; P < 0.001), calcium (76% versus 33%, respectively; P < 0.001), phosphorus (63% versus 50%, respectively; P = 0.002), and PTH and Ca x P (59% versus 16%, respectively, P < 0.001), and allowed a 22% reduction in vitamin D dosage in patients receiving vitamin D at baseline. Achievement of targets was greatest in patients with less severe disease (intact PTH range, 300 to 500 pg/ml) and the cinacalcet dose required was lower in these patients (median = 30 mg/d).nnnCONCLUSIONSnCompared with conventional therapy, a cinacalcet-based treatment algorithm increased achievement of KDOQI treatment targets in dialysis patients in whom conventional therapy was no longer effective in controlling this disease.
Archive | 2009
Henrique Luz; António Vaz Carneiro; António M. N. Cabrita; Fernando Carrera; João M. Frazão; Fernando Macário; Pedro Leão Neves; Fernando Nolasco; Pedro Ponce; Mateus Martins Prata; José Vinhas
Archive | 2015
Aníbal Ferreira; Inês Aires; Fernando Nolasco; Domingos Machado; Fernando Macário; Pedro Leão Neves; António Gomes da Costa; António M. N. Cabrita; Rui Castro; João B. Pereira
Archive | 2015
Luís Rodrigues; Fernando Macário; Cátia Pego; Marta Neves; Catarina Romãozinho; Lídia Santos; Rui Alves; Helena Sá; Alfredo Mota; Mário Campos
Archive | 2014
Rita Leal; Tânia Santos; Ana Galvão; Fernando Macário; Jorge Pratas; Fernanda Xavier Cunha; Laura Vilarinho; Mário Campos
Archive | 2011
Susana Machado; Francisco Ferrer; Nuno Viana; Fernando Macário; Rui Alves; Alfredo Mota
Archive | 2011
Carlos Botelho; Patrícia Aires; Lídia Santos; Catarina Romãozinho; Pedro Veiga; Fernando Macário; Rui Alves; Alfredo Mota
Archive | 2010
Francisco Ferrer; Susana Machado; Carlos Botelho; Fernando Macário; Rui Alves; Pedro Maia; Armando Carreira; Alfredo Mota
Revista Portuguesa de Nefrologia e Hipertensão | 2009
Fernando Macário; João M. Frazão; Aníbal Ferreira; André Weigert; Márcia Mota; Domingos Machado; Rita Birne; Ricardo Neto; A. Baldaia Moreira; Carlos Soares; Silvia Ribeiro; Teresa Mendes; Rui Alves; Henrique V. Gomes; Helena Raposo
Archive | 2009
Lídia Santos; Fernando Macário; Rui Alves; Alfredo Mota; Mário Campos